Additionally, increased FGF2 expression in bevacizumab-resistant HNSCC cells, accompanied with upregulation of PLCγ, ERKs, and AKT, correlated with the reduced sensitivity to the bevacizumab treatment [53]. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.